Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200974 | 0.82 | KMT2A (0.50) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL4198980 | 0.79 | MEN1 (0.47) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL18795129 | 0.76 | TDP1 (0.48) | ALOX15HSD17B10TDP1LMNARXFP1 | |
| SCHEMBL10808828 | 0.73 | MEN1 (0.59) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL4208885 | 0.73 | MEN1 (0.44) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL5501071 | 0.70 | MEN1 (0.42) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL13227193 | 0.70 | MAPT (0.51) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL28182439 | 0.69 | MEN1 (0.57) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL31325782 | 0.69 | L3MBTL1 (0.43) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL28277834 | 0.68 | POLB (0.45) | KMT2ATDP1KDM4EGAATUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-7452996-B2 | Substituted quinoline derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452996-B2 | Substituted quinoline derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452996-B2 | Substituted quinoline derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1753723-B1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1753723-B1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-08-13 | — | — | EP | disclosed |
| CN-1956960-A | Substituted quinoline derivatives as mitotic kinesin inhibitors | CHIRON CORP (US) | 2007-05-02 | — | — | CN | disclosed |
| EP-1753723-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005113507-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050261337-A1 | N-(3-aminopropyl)-N- [1-(3-benzylquinolin-2-yl)- 2-methylpropyl]-3-fluoro-4-methylbenzamide; cancer; disorder mediated, at least in part by kinesin-related proteins | WANG WEIBO | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | ABCG2, ABCB1, UGT2B7 | KMT2A 2420/4885MEN1 1972/4885CYP3A4 15/4885 |
| US-20050261337-A1 | N-(3-aminopropyl)-N- [1-(3-benzylquinolin-2-yl)- 2-methylpropyl]-3-fluoro-4-methylbenzamide; cancer; disorder mediated, at least in part by kinesin-related proteins | KIF5B, KIF2C, KIF5C | KMT2A 429/4885MEN1 3090/4885CYP3A4 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.